Published in Blood Weekly, May 25th, 2006
"HCV is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide, and is the main cause of adult liver transplants in developed nations. We have identified a class of novel and specific inhibitors of HCV NS5B RdRp activity in vitro," wrote G. Lee and colleagues, Amgen Inc.
"Characterization of two such inhibitors, COMPOUND1 (5-(4-chlorophenylmethylene)-3-(benzenesulfonylamino)4-oxxo-2-thionothiazolidine) and COMPOUND2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.